Dabrafenib-trametinib combination active in BRAF-mutated biliary tract cancer

The combination of dabrafenib and trametinib appeared active among patients with BRAF V600E-mutated biliary tract cancer, according to results of an ongoing phase 2 basket trial published in The Lancet Oncology.Approximately half of patients achieved response, and the combination also exhibited a manageable safety profile.“The results … [support] the use of this combination therapy as a treatment option for patients with BRAF V600E-mutated biliary tract cancer,” researcher Vivek Subbiah, MD, associate professor in the department of investigational cancer therapeutics at TheRead More

Share on facebook
Share on twitter
Share on linkedin